In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Surrozen, with a price target of $32.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Caufield has given his Buy rating due to a combination of factors related to Surrozen’s innovative approach in treating retinal diseases. The company has recently showcased promising preclinical data for its assets SZN-8141 and SZN-8143, which focus on modulating the Wnt pathway to promote retinal vascular repair and regeneration. This approach has demonstrated potential in reducing abnormal vessel growth and enhancing normal vessel regrowth, which is crucial for treating conditions like diabetic macular edema and wet age-related macular degeneration.
Additionally, Caufield highlights the strategic importance of the Wnt pathway, noting its validation through significant industry moves such as Merck’s acquisition of EyeBio and Roche’s acquisition of AntlerA. Despite the discontinuation of a previous candidate for a different indication, the analyst remains optimistic about the potential of Wnt-mediated therapies. The collaboration with Boehringer Ingelheim for SZN-413 further reinforces the potential and validation of Surrozen’s approach, providing additional opportunities beyond their internal pipeline.